Research coverage runs from preclinical mechanism papers to AI-driven peptide discovery. Most of what shows up here lives in Nature, Cell, Science, JAMA, and the abstracts from AACR, ESCMID, AAN, and ESCMID Global.
A few threads keep recurring. Macrocyclic and bicyclic peptides keep getting better at hitting "undruggable" targets — KRAS, beta-catenin, intracellular protein–protein interactions. Antimicrobial peptides have moved from theory to clinical candidates against carbapenem-resistant organisms and biofilms. Cancer peptide vaccines (ELI-002, autogene cevumeran, EVX-01) are producing real survival data. AI design tools — protein language models, transformer architectures, de novo platforms — are starting to generate hits that humans wouldn't.
If you want the lab side without the press releases, this is the right surface. The stories below name the lab, the journal, and the result.
Mikhail Kolonin's group at UTHealth Houston published preclinical data showing BLMP6, a peptide identified through AI-guided modeling, selectively binds fibulin-4 — a protein highly expressed on metastatic triple-negative breast cancer cells — and not on noninvasive breast cancer or normal breast tissue. A BLMP6 conjugate carrying monomethyl auristatin E suppressed metastasis and improved survival in mouse models, and BLMP6-based fluorescent imaging probes successfully detected metastatic lesions. The paper, published in Molecular Therapy Oncology, identifies fibulin-4 as a new theranostic target.
A Nature Communications paper describes a deep-learning pipeline that uses pre-trained protein language models combined with few-shot fine-tuning to identify antimicrobial peptides effective against Acinetobacter baumannii, a WHO critical-priority pathogen. The classification, ranking, and regression modules collaboratively prioritize candidates with high predicted activity, expanding the chemical space accessible to data-poor AMR targets. Lead candidates showed potent in vitro activity against carbapenem-resistant clinical isolates.
A Nature paper from Liskiewicz, DiMarchi, Tschöp, Müller and colleagues introduces a unimolecular peptide-drug conjugate that combines a GLP-1R/GIPR co-agonist peptide with the pan-PPAR (α/γ/δ) agonist lanifibranor via a pH-sensitive linker. After receptor-mediated internalization, the linker cleaves and lanifibranor escapes to the nucleus to activate PPARs while the peptide moiety drives GLP-1R/GIPR signaling at the membrane. In obese, diabetic mice the conjugate produced greater weight loss and insulin sensitization than equimolar dosing of the unconjugated peptide and lanifibranor, without the typical PPAR-related cardiac and weight-gain safety signals.
A Stanford-led study published March 29 in Genome Medicine, with broad media coverage in late April, identifies two genetic variants that handicap the PAM enzyme (peptidyl-glycine alpha-amidating monooxygenase) responsible for activating GLP-1 and other peptide hormones. In a meta-analysis of three trials with 1,119 participants, carriers — roughly 10% of the general population — were less responsive to GLP-1 drugs and saw smaller HbA1c reductions despite higher circulating GLP-1 levels. The work is the first in-depth investigation of a 'GLP-1 resistance' phenotype, sits alongside the recent 23andMe GLP1R/GIPR variant paper, and opens a path toward genetically-stratified incretin prescribing.
A PLOS Computational Biology paper published April 28 introduced MsgaBpred, a multi-scale graph attention model for predicting B-cell epitopes — short peptide sequences recognized by antibodies. The model achieved high accuracy on cross-species benchmarks and is directly relevant for peptide vaccine antigen design, diagnostic peptide development, and antibody-target discovery. The work joins the broader 2026 wave of AI-driven peptide tooling, complementing the Nature Communications DDA-BERT and CycloSEL papers from earlier in the month.
A 2026 Scientific Reports paper characterized the biophysical and aerodynamic properties of PI3Kγ MP (KIT2014), a non-natural peptide that disrupts the AKAP-PKA interaction by mimicking PI3Kγ's A-kinase anchoring function. The peptide adopts a partially structured conformation essential for PKA binding, assembles into dynamic nanoparticles compatible with epithelial and mucus penetration, and retains full biological activity in protease-rich environments — enhancing β₂-adrenergic receptor-driven cAMP signaling to promote airway relaxation, mucus clearance, and reduced inflammation in pulmonary cells. The work builds the case for peptide-based AKAP disruptors as inhaled therapeutics for chronic inflammatory airway diseases including asthma and COPD.
A post-hoc analysis in the International Journal of Cancer tracked 51 patients from the Mel39 randomized phase II trial of multipeptide vaccination for resected high-risk melanoma. At median follow-up of 16.1 years (21.2 years for surviving participants), the 12-peptide vaccine arm reported 65% 10-year and 49% 20-year overall survival vs. the 4-peptide arm (HR 0.64, 95% CI 0.29–1.40). The 20-year dataset represents among the longest published follow-up for any cancer peptide vaccine and reinforces that antigen breadth drives durability; sex-specific differences were documented, with females showing improved recurrence-free survival.
A Nature Communications paper published April 27 mined natural diversity in Viola plants to discover 29 new peptide asparaginyl ligases (PALs) — enzymes that catalyze cyclization of synthetic peptide chains. The work characterizes a pH-dependent cyclization mechanism and defines transferable expression-increasing principles, substantially expanding the enzymatic toolkit available for cyclic peptide drug development. The discovery is timely given the surge of macrocyclic peptide programs at Circle Pharma, Bicycle Therapeutics, and Unnatural Products.
A Nature Communications paper published April 27 introduced DDA-BERT, an end-to-end transformer-based deep learning model for peptide identification in data-dependent acquisition (DDA) proteomics. The model improves peptide identification accuracy across multiple species and outperforms existing methods on HLA immunopeptidomics — directly relevant to neoantigen peptide vaccine discovery for personalized cancer immunotherapy. The work joins the broader 2026 wave of AI-driven peptide tooling captured in this month's ACS Biochemistry and Nature Biotechnology papers.
A Nature Biotechnology paper introduced a user-defined peptide library platform that enables sensitive detection of cancer antigens — relevant for both cancer immunotherapy target identification and neoantigen vaccine design. The platform allows researchers to design peptide pools customized to specific tumor types or HLA profiles, accelerating the antigen-discovery bottleneck in personalized cancer vaccine development. Builds on the same proteomic technology stack advancing across multiple peptide-vaccine programs at BioNTech, Genentech, and emerging neoantigen biotechs.
A Nature Communications paper introduced genetically encoded CRAC (calcium release-activated calcium) channel inhibitory binders — designated CRABs — derived from the ORAI C-terminal tail. Membrane-anchored CRAB variants potently inhibit Ca²⁺ influx and downstream NFAT signaling, offering a peptide-based modulator class for channelopathies, autoimmune disorders, and cancer immunotherapy applications. The mechanism complements existing CRAC channel small-molecule inhibitors and expands the toolkit for precision modulation of calcium signaling.
AJSM published a comprehensive review of injectable peptide therapy for orthopedic and sports medicine, surveying BPC-157, TB-4, TB-500, CJC-1295 + ipamorelin, tesamorelin, and GHK-Cu. The authors conclude that while preclinical evidence supports tendon and muscle repair benefits, human trials are minimal — the most-cited BPC-157 human data is a single 12-patient case series with significant methodological flaws. TB-500 and BPC-157 remain WADA-banned. The piece directly addresses surgeons being asked about peptides by patients in the wake of FDA Category 2 changes.
A qualitative research study published in Sports Health (Sage Journals) analyzed Reddit user perspectives on peptide therapy after orthopedic surgery, capturing patient experiences with BPC-157, TB-500, and combination protocols (KLOW, GLOW). The study documents how patients are sourcing peptides outside the regulated medical system, often without physician oversight, and provides one of the few peer-reviewed snapshots of the gray-market peptide community as the FDA July PCAC review approaches.
The American Orthopaedic Society for Sports Medicine published an April 2026 update revisiting the evidence base for peptide therapy in sports medicine. The piece reflects increasing surgeon-side concerns about patients self-administering peptides for recovery from injuries and surgeries, with growing pressure from clinics offering BPC-157 and TB-500 injections. AOSSM's stance remains that current evidence is insufficient to recommend therapeutic peptide use — but the educational push acknowledges the rising clinical reality post-FDA reclassification.
A 2025-2026 PubMed-indexed review (PMID 41490200) consolidates the orthopedics-focused therapeutic peptide literature, covering bone graft peptides (P-15, BMP-2 mimetics), tendon repair peptides (BPC-157, TB-500), cartilage peptides (Cartalax, anti-myostatin agents), and clinical translation challenges. Cerapedics' PearlMatrix P-15 is highlighted as one of the few FDA-cleared peptide-enhanced orthopedic products — context for the company's Vizient supplier deal earlier this week.
An ACS Biochemistry paper published April 10 examined the maturation of AI-designed peptides as tools for biochemistry research and therapeutic development. The work covers computational design of cyclic peptides, antimicrobial peptides, and peptide ligands with novel binding specificities — capturing the moment when machine-learning-driven peptide design has begun delivering candidates competitive with traditional medicinal-chemistry approaches across multiple modality categories.
A January 2026 Frontiers in Cellular and Infection Microbiology review synthesized the case for antimicrobial peptides (AMPs) as the most promising response to antimicrobial resistance, which is responsible for nearly 5 million deaths annually and projected to double by 2050. The review emphasizes that AMPs' rapid, multi-target mechanism — primarily physical membrane disruption — produces significantly lower incidence of resistance emergence than traditional small-molecule antibiotics. The pipeline now exceeds 150 active candidates spanning AI-designed AMPs, lysin-derived peptides, and venom-derived sequences.
Recent reviews and real-world observation studies aggregate the state of peptide-vaccine immunotherapy for glioblastoma. A 2024 Nature Communications real-world observational study reported clinically meaningful outcomes for personalized peptide vaccines; the UCPVax + temozolomide trial (NCT04280848) showed 97% anti-TERT immune response, 48% epitope spread, median OS 17.9 months, and 26% alive at 2 years. The peptide-vaccine modality is one of multiple approaches (mRNA, dendritic cell, neoantigen) advancing alongside immune checkpoint blockade.